Fraser, Mark E.Kucharski, CherylLoh, ZoeHanahoe, ErinFraser, Malcolm J., Jr.2024-10-282024-10-282024Fraser ME, Kucharski C, Loh Z, Hanahoe E, Fraser MJ Jr. Design and testing of Hepatitis Delta Ribozymes for suppression of Chikungunya virus infection in cell cultures. Med Res Arch. 2024;12(8):10.18103/mra.v12i8.5762. doi:10.18103/mra.v12i8.5762https://hdl.handle.net/1805/44263Chikungunya virus is an emerging pathogen with widespread distribution in regions of Africa, India, and Asia that threatens to spread into temperate climates following the introduction of its major vector, Aedes albopictus. Recent cases have been documented in Europe, the Caribbean, and the Americas. Chikungunya virus causes a disease frequently misdiagnosed as Dengue fever, with potentially life-threatening symptoms that can result in long term debilitating arthritis. There have been ongoing investigations of possible therapeutic interventions for both acute and chronic symptoms, but to date none have proven effective in reducing the severity or lasting effects of this disease. Recently, a promising vaccine candidate has received accelerated approval, indicating the importance of remedies to this emerging worldwide health threat. Nonetheless, therapeutic interventions for Chikungunya and other mosquito borne virus diseases are urgently needed yet remain elusive. The increasing risk of spread from endemic regions via human travel and commerce, coupled with the absence of a vaccine or approved therapeutic, puts a significant proportion of the world population at risk for this disease. In this report we explore the possibility of using Specific On/oFf Adapter Hepatitis Delta Virus Ribozymes as antivirals in cells infected with Chikungunya virus. The results we obtained suggest there could be some role in using these ribozyme molecules as antiviral therapies for not only Chikungunya virus, but potentially other viruses as well.en-USPublisher PolicyAntiviralCHIKVChikungunyaHepatitis DeltaRibozymeArticle